Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cagrilintide vs Dulaglutide (Trulicity)
An educational, source-based comparison of Cagrilintide and Dulaglutide (Trulicity) — how each peptide works, what it's researched for, and what to know before going deeper.
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes
- • Investigational; not yet FDA-approved as monotherapy.
- • GI side effects similar to GLP-1 agonists.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cagrilintide | Cagrilintide plus semaglutide for obesity (Phase 2) | The Lancet | 2021 | Combination produced greater weight loss than either agent alone. |
| Dulaglutide (Trulicity) | REWIND trial | Lancet | 2019 | Reduced major adverse cardiovascular events in T2D patients with or without prior CV disease. |
Side-effect & safety grid
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.
- FDA-approved.
- Boxed warning: thyroid C-cell tumors in rodents.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cagrilintide vs Dulaglutide (Trulicity) — Key differences
- Class: Cagrilintide is classified as Metabolic · Amylin, while Dulaglutide (Trulicity) is GLP-1 Agonist · Metabolic.
- Primary research focus: Cagrilintide — weight management as monotherapy and combined with semaglutide (cagrisema); Dulaglutide (Trulicity) — type 2 diabetes.
- Tag: Weight loss vs FDA-Approved · Metabolic.